SHANGHAI HENLIUS BIOTECH, INC. DelveInsight's, "Triple Negative Breast Cancer Pipeline Insight 2024" report provides comprehensive insights about 75+ companies and 80+ pipeline drugs in Triple Negative Breast Cancer pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Key Takeaways from the Triple Negative Breast Cancer Pipeline Report
*DelveInsight's Triple Negative Breast Cancer Pipeline analysis depicts a robust space with 75+ active players working to develop 80+ pipeline treatment therapies. *The leading Triple Negative Breast Cancer Companies working in the market include
Request a sample and discover the recent advances in Triple Negative Breast Cancer @ Triple Negative Breast Cancer Pipeline Outlook Report
Triple Negative Breast Cancer Overview
Triple Negative Breast Cancer (TNBC) is defined as a tumor where the estrogen and progesterone (ER/PR) are negative, as assessed by immunohistochemistry (IHC), and there is a lack of overexpression of HER2, as assessed by immunohistochemistry (IHC), or the absence of its gene amplification, as assessed by fluorescence in situ hybridization technique. The epidemiological risk factor profiles also vary between TNBC (ER-PR-HER2-) and other breast cancers. TNBCs are frequently identified as hyper dense masses without associated calcifications.
Triple-negative breast cancer has fewer treatment options than other types of invasive breast cancer. This is because the cancer cells do not have the estrogen or progesterone receptors or enough of the HER2 protein to make hormone therapy or targeted HER2 drugs work. Because hormone therapy and anti-HER2 drugs are not choices for women with triple-negative breast cancer, chemotherapy is often used. If the cancer has not spread to distant sites, surgery is an option.
Triple Negative Breast Cancer Emerging Drugs
*Camrelizumab:
Camrelizumab (Airuika) is a humanized monoclonal antibody acts as immunomodulatory agent. It is formulated as solution for intravenous route. Camrelizumab is indicated as third-line treatment for recurrent or refractory classical hodgkin's lymphoma, advanced hepatocellular carcinoma patients with oxaliplatin system chemotherapy, combined with pemetrexed and carboplatin for epidermal growth factor receptor (EGFR) gene mutation negative and anaplastic lymphoma kinase (ALK) negative, non-resectable locally advanced or metastatic first-line treatment of non-squamous non-small cell lung cancer (NSCLC), locally advanced or metastatic esophageal squamous cell carcinoma patients who have previously received first-line chemotherapy and whose disease has progressed or become intolerable and for the treatment of patients with advanced nasopharyngeal carcinoma who had disease progression after previous second-line and above chemotherapy or intolerable treatment. Currently the drug is in Phase III stage of Clinical trial evaluation for the treatment of Triple Negative Breast Cancer.
*IPI-549:
IPI-549 is under development for the treatment of solid tumors including metastatic renal cell cancer, soft tissue sarcoma and prostate cancer, triple negative breast cancer, colon cancer, metastatic melanoma, non-small cell lung cancer, glioblastoma multiforme, microsatellite-stable gallbladder carcinoma, head and neck cancer squamous cell carcinoma, mesothelioma, ovarian cancer, adrenocortical carcinoma and metastatic urothelial cancer including renal pelvis cancer, ureter cancer, bladder cancer, urethra cancer.
*PMD-026: Phoenix Molecular Designs
PhoenixMD's lead candidate, PMD-026, is the first RSK inhibitor being developed for the treatment of TNBC. It is a pill that is convenient for patients as opposed to intravenous delivery, the mode most commonly used to deliver chemotherapy. PMD-026 was designed for TNBC because RSK2 was specifically identified as the key kinase that drives the growth of this breast cancer subtype5, 6. PMD-026 is well-tolerated in breast cancer patients and can stop tumor growth for up to 5 months based on Phase 1 data.
Learn more about Triple Negative Breast Cancer in clinical trials @ Triple Negative Breast Cancer Drugs
Triple Negative Breast Cancer Therapeutics Assessment
There are approx. 75+ key companies which are developing the therapies for Triple Negative Breast Cancer. The Triple Negative Breast Cancer companies which have their Triple Negative Breast Cancer drug candidates in the most advanced stage, i.e. phase III include,
DelveInsight's Triple Negative Breast Cancer Pipeline report covers around 80+ products under different phases of clinical development like
*Late stage products (Phase III) *Mid-stage products (Phase II) *Early-stage product (Phase I) along with the details of *Pre-clinical and Discovery stage candidates *Discontinued & Inactive candidates
Discover more about Triple Negative Breast Cancer in development @ Triple Negative Breast Cancer Clinical Trials
Triple Negative Breast Cancer Companies
Triple Negative Breast Cancer pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
*Oral *Parenteral *intravenous *Subcutaneous *Topical.
Triple Negative Breast Cancer Products have been categorized under various Molecule types such as
*Monoclonal Antibody *Peptides *Polymer *Small molecule *Gene therapy
To know more about Triple Negative Breast Cancer, visit @ Triple Negative Breast Cancer Segmentation
Scope of the Triple Negative Breast Cancer Pipeline Report
*Coverage- Global *Triple Negative Breast Cancer Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination *Triple Negative Breast Cancer Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III *Triple Negative Breast Cancer Companies-
For further information on the Triple Negative Breast Cancer Pipeline Therapeutics, reach out @
Table of Content
*Introduction *Executive Summary *Triple Negative Breast Cancer: Overview *Pipeline Therapeutics *Therapeutic Assessment *Triple Negative Breast Cancer - DelveInsight's Analytical Perspective *Late Stage Products (Phase III) *Camrelizumab:
About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Media Contact
Company
Contact Person:
Email: info@delveinsight.com
Phone: 09650213330
Address:
City:
State: NV
Country:
Website: https://www.delveinsight.com/
Source: www.abnewswire.com
.
(C) 2024 M2 COMMUNICATIONS, source
